drugset / Trial / NCT04410874

Imvamune Vaccine for the Treatment of Non-melanoma Skin Cancer

NCT04410874

Phase 1/2 Terminated 1 enrolled Ivan Litvinov
NaSequentialOpen-labelTreatment

Summary

This study examines the safety and efficacy of using the Imvamune smallpox vaccine in the treatment of non-melanoma skin cancers (basal cell carcinoma and squamous cell carcinoma).

Timeline

Start
2020-11-16
Primary completion
2023-05-23
Completion
2023-05-23

Drugs

EvaluationDrugModalityDoseRoute
Subject IMVAMUNE Vaccine 1e+07 unknown Other
Subject IMVAMUNE Vaccine 1e+08 unknown Other
Subject IMVAMUNE Vaccine 4e+08 unknown Other